The Coverage Landscape for Obesity Treatment
A new coverage guide on my site, the states and employers that pulled back this week, and why turning treatment on and off is the most expensive choice of all.
Demand for obesity treatment has never been higher. Medicare signed up hundreds of thousands of people in three months, and patients are protesting when their employers take treatment away. And yet this week the insurance plans that pay for that treatment kept pulling back: another state Medicaid program, the health plans of several household-name employers, and a shrinking menu of Medicare drug plans. So I built one place to see who covers what. Here is what changed, what it means, and what to do about it.
Will insurance cover obesity treatment?
DougMareadyMD.com/insurance-coverage · Medicaid status verified weekly
The most common question I get in clinic is not about side effects or dosing. It is "will my insurance pay for this?" The honest answer has always been "it depends," and that answer is not useful to anyone. So I built a page that turns "it depends" into a short, specific answer for your situation.
Coverage depends on three things: who pays for your plan, the state you live in, and the reason written on the prescription. The page starts with your type of insurance and gives you the short answer first, then the detail:
- Medicare. The $50-a-month GLP-1 Bridge for Wegovy, Zepbound KwikPen, or Foundayo, with an eight-step "do you qualify" walkthrough of the BMI-plus-condition grid. Plus the benefits Medicare has quietly covered for years, like intensive behavioral therapy since 2011.
- Medicaid. An interactive state map, rechecked every Monday against state Medicaid notices, prior authorization forms, budgets, and legislation, with the date it was last verified printed right on it.
- Who flipped. A month-by-month chart of every state that has changed its answer since mid-2024. There have been 16 changes. North Carolina dropped coverage and brought it back ten weeks later.
- Employer plans. The latest employer survey data and the specific questions to ask HR or your plan.
- Marketplace and self-pay. Manufacturer cash prices as of October 1, now starting around $149 a month for the pill forms.
- Arizona. Where we stand on AHCCCS, Medicare, the state employee plan, and the legislature.
Bookmark it. Send it to the person in your family who keeps asking. If you are a clinician, send it to your front desk, because they get this question more than you do.
Eight things that moved
September 27 to October 2, 2026 · sources linked in each item
1. Rhode Island Medicaid cut coverage on October 1
Rhode Island Medicaid no longer covers Wegovy, Zepbound, Saxenda, or Foundayo when prescribed for weight loss alone. There is no grandfathering, so people already on treatment lost coverage on the same day as everyone else. The drugs are still available for other FDA-approved uses, like type 2 diabetes, but that requires a new prior authorization. The state estimated savings of $6.3 million in state funds and $20.3 million counting federal dollars, and it has not said how many people lost coverage.
That leaves 10 state Medicaid programs that cover obesity medication, and three of those only for severe obesity. Seven states have ended coverage since late 2025. Two are moving the other way: Indiana announced it will cover through the federal BALANCE model, and Louisiana passed a law to expand coverage on January 1, 2027, though the funding has not been identified.
Rhode Island EOHHS provider notice · Providence Business News · State-by-state map
2. Massachusetts is hearing the pushback
Martin Luther King III, state Rep. Marjorie Decker, and others urged Massachusetts to reverse two decisions: MassHealth dropping GLP-1 coverage for weight loss in its fiscal 2027 budget, and the state employee plan (the GIC) voting in February to drop it too. The GIC was spending about $46 million a year on these drugs for roughly 22,000 members. The state's Health and Human Services secretary predicted coverage would come back once prices fall. Nothing has changed yet, but it is the clearest example this year of a state cutting coverage to save money and hearing loudly about the equity cost.
3. Household-name employers are pulling back
Cigna stopped covering GLP-1s for weight loss for its own employees on July 1. Employees told reporters their monthly cost went from about $25 to about $500, and more than 450 signed a petition asking the company to reconsider. Read that again: a health insurer decided this benefit was not worth it for its own workforce. PepsiCo ends coverage this month; the notice to employees called these drugs "one of the fastest-growing costs" in its plans and pointed them to cash-pay options. Starbucks ends coverage for weight loss this month too, while keeping it for diabetes.
The surveys show the same direction. The Business Group on Health found the share of large employers covering these drugs for weight loss fell from 72% in 2025 to 60% in 2026. And in June, a federal court in Washington, D.C. upheld an employer plan that excluded "weight loss drugs" even for Zepbound, which is also approved for sleep apnea. If your plan language excludes weight-loss drugs, do not assume a second FDA indication forces coverage.
Bloomberg · WFSB · Becker's · HR Katha · SHRM · HCAMag
4. CVS Caremark put Zepbound back on its formulary
CVS dropped Zepbound in July 2025 when Wegovy won preferred status. As of October 1, it is back. Wegovy is still preferred, but patients on CVS Caremark plans can now choose either one, with copays as low as $25 a month for eligible commercial patients and $50 for Medicare patients through the Bridge. A small step in the other direction, and a reminder that formulary decisions are reversible.
5. Medicare's Bridge is filling fast
Eli Lilly's CEO said about 700,000 new seniors have started a GLP-1 since the Medicare GLP-1 Bridge launched July 1, with about 70% on Lilly drugs. That is the company's count, not an official CMS number. At a national advocacy meeting this week I heard that the real enrollment is closer to a million and simply has not been reported yet. Either way, demand is there. The Bridge ends December 31, 2027, and nothing permanent has been announced to replace it.
CNBC · Do you qualify? The Medicare walkthrough
6. Fewer Medicare drug plans for 2027
The 2027 Part D lineup is out. Stand-alone drug plans drop about 13%, from 360 to 312, and there will be no $0-premium stand-alone plans for people without Extra Help. GLP-1 costs were named as one source of premium pressure. Open enrollment runs October 15 to December 7. If you or a parent is on Medicare, compare plans this year rather than letting last year's roll over.
7. Prices fall in January
Novo Nordisk's list price cut for Wegovy and Ozempic, to about $675 a month, takes effect January 1, 2027. Manufacturer cash prices are already far below where they were a year ago, starting around $149 a month for the pill forms. More competition arrives in 2027 through 2029. Anyone making a coverage decision on last year's price is using the wrong number.
CBS News · Current self-pay prices
8. The State of Obesity 2026 report is out
Trust for America's Health released its annual report on October 1. The headline is cautiously good: after decades of rising adult obesity rates, they are finally leveling off. But about 4 in 10 adults still have obesity, and 21 states are at or above 35%. The report's policy asks focus on prevention funding and food security. Those matter. So does treating the people who already have the disease, and that is the part the coverage decisions above keep cutting.
On-again, off-again coverage is the costliest option
Wilding JPH et al. Diabetes Obes Metab. 2022;24(8):1553-1564 · Aronne LJ et al. JAMA. 2024;331(1):38-48
Every one of the decisions above is framed as saving money. Here is what the trials say happens to the patient when the benefit turns off.
In the STEP 1 extension, people who stopped semaglutide regained two-thirds of the weight they had lost within a year, and their blood pressure, blood sugar, and cholesterol drifted back toward where they started. In SURMOUNT-4, people switched from tirzepatide to placebo regained 14% of their body weight over the next year, while those who stayed on treatment lost another 5.5%.
Obesity is a chronic disease. We do not stop blood pressure medication when the blood pressure looks good and expect it to stay there. When coverage stops, treatment stops, and the health gains go with it. The plan has paid for the expensive first year and gets back very little of what it bought.
I see this pattern in Arizona, where some of our largest employers have covered these drugs, dropped them, covered them again, and dropped them again. Every flip resets the clock for the patient and wastes what the plan already spent. If a plan cannot commit to covering treatment, the second-best choice is not to cut it abruptly; it is to protect the people already mid-treatment. National advocates I met with this week are starting to study exactly this, and I am adding it to the cost-of-inaction work we are doing through the Arizona Obesity Organization.
What it costs us not to treat obesity
The Dr. Francavilla Show, Episode 203: GLP and Obesity Treatment Coverage with Dr. Doug Maready · link starts at the cost discussion
Every coverage decision this week was made by looking at one side of the ledger: what the drugs cost. The other side rarely gets added up. Obesity reduces Arizona's economic activity by about $11.1 billion a year, roughly 1.8% of the state's GDP, once you count healthcare, lost workdays, workers' compensation, and lost tax revenue. That bill arrives every year whether anyone pays for treatment or not.
On The Dr. Francavilla Show, I walked through that number, why we never ask a heart attack or a cancer diagnosis to pay for itself, and what people can do when their plan says no. If your employer is weighing its 2027 benefits right now, this is a good episode to send to HR.
Five questions before the 2027 renewal
Adapted from the employer section of the Insurance Coverage page
Most people with private insurance get it through work, and the employer decides whether obesity medication is in the plan. If you advise employers or sit on the benefits side, these are the questions I would want answered before renewal:
- Are anti-obesity medications covered, or written in as an exclusion? Look at the plan documents, not the summary.
- If covered, what are the criteria to start and to stay on? BMI, prior authorization, required lifestyle program, and the weight-loss threshold for renewal.
- Are the same drugs covered for other conditions when obesity is excluded? Wegovy for heart disease, Zepbound for sleep apnea. After this year's court ruling, the exclusion language matters.
- Is the rest of the treatment ladder covered? Obesity counseling (most plans must cover it at no cost under ACA preventive services rules), dietitian visits, and bariatric surgery.
- If coverage ends, what happens to people mid-treatment? A transition period, a taper, or a cash-pay pathway is far better than a cliff.
And price it with January's numbers, not last year's. List prices drop on January 1, more competitors are coming, and the cost of stopping treatment belongs on the same spreadsheet as the cost of starting it.
Check your coverage any time at DougMareadyMD.com/insurance-coverage. This newsletter is general information, not medical, insurance, or legal advice. Coverage depends on your specific plan and state.